SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-129868
Filing Date
2023-12-28
Accepted
2023-12-28 07:00:12
Documents
14
Period of Report
2023-12-27
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2333798d1_8k.htm   iXBRL 8-K 29185
2 EXHIBIT 10.1 tm2333798d1_ex10-1.htm EX-10.1 50315
3 EXHIBIT 10.2 tm2333798d1_ex10-2.htm EX-10.2 29036
  Complete submission text file 0001104659-23-129868.txt   297441

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nbse-20231227.xsd EX-101.SCH 3048
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbse-20231227_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbse-20231227_pre.xml EX-101.PRE 22381
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2333798d1_8k_htm.xml XML 3226
Mailing Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219
Business Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219 412-763-3350
NeuBase Therapeutics, Inc. (Filer) CIK: 0001173281 (see all company filings)

IRS No.: 465622433 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35963 | Film No.: 231519299
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)